Thanks RL,
All the best to you also & thanks again for your input here. I think they were waiting on results from both trials to do secondary analysis.
I also think that possibly SGLT2 drugs thrown into the mix may have had something to do with results, as this was a bit of a common theme throughout the presentation. Nina also said there was no fundamental reason that DMX-200 could not be prescribed with SGLT2 drugs & ARB for an additive effect & Professor Roger also discussed this as well. This will be interesting & if DMX-200 is showing an additive effect on top of SOC ARB + SGLT2, with no adverse drug interactions, this could be very commercially attractive to Big Pharmas all vying for the lion share of the CKD/DKD market.
Is it possible that DMX-200 has had a longer lasting effect once odd treatment, dampening down inflammation in the kidneys for patients who weren’t as sick, and therefore changed the course of the disease as Prof Packham discussed this possibility resulting in legacy effect on placebo in these 14 patients with <500mg/g baseline & which patients were on SGLT2 & which treatment cohorts? Many questions in my head, but guess we will find out soon enough.
- Forums
- ASX - By Stock
- DXB
- Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-342
-
-
- There are more pages in this discussion • 286 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
44.0¢ |
Change
-0.005(1.12%) |
Mkt cap ! $242.2M |
Open | High | Low | Value | Volume |
44.5¢ | 45.3¢ | 43.0¢ | $442.7K | 1.009M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1739 | 44.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
44.5¢ | 18062 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1739 | 0.440 |
3 | 123891 | 0.435 |
1 | 18062 | 0.430 |
4 | 54962 | 0.425 |
4 | 73413 | 0.420 |
Price($) | Vol. | No. |
---|---|---|
0.445 | 18062 | 1 |
0.450 | 43062 | 2 |
0.455 | 95198 | 3 |
0.460 | 76666 | 3 |
0.465 | 39700 | 2 |
Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online